

Electronic Certificate

Version: 4 . 0

Document Number: MAT-US-2109597

Document Name: Sanofi Patient Connection (SPC) - Program Application (English)

Country: United States

Adacel Admelog Apidra General Corporate Imogam Rabies-HT Imovax

Product: Rabies Lantus Lovenox MenQuadfi Mozobil Multaq Pentacel Priftin Soliqua

Tenivac Thymoglobulin Thyrogen Toujeo

Type: Material

Sub Type:

Classification:

Certification Statement

We certify that the final electronic form of this material is in accordance with the regulations set forth by the health authority for the country of this document, and is a fair and truthful presentation of the facts about the product.

Role	Signature
Elinor Lovich - Final Form Inspection (E0526511@sanofi.com)	Meaning: As the Final Form Inspection, I approve this document for use. Date: 06-Oct-2023 18:52:48 GMT+0000





Sanofi Patient Connection® is a program (the "Program") to help you get access to the medications and resources you need at no cost. Patient Assistance Connection is part of the Program that provides select Sanofi prescription medications and vaccines, at no cost, if you meet certain eligibility requirements. Patient Assistance Connection is made possible through Sanofi Cares North America.

Regarding use of Authorized Representatives:

While patients are free to authorize family, care team members, or third-party representatives to complete and manage their Sanofi Patient Connection application please be aware that:

- The application can be fully completed by the patient and their licensed healthcare provider (HCP).
- Sanofi Patient Connection does not charge any fees for this service; application processing, medication, and shipping are all
 offered at no cost. Any fees charged to you by a third party completing this application on your behalf are not required by nor
 remitted to Sanofi.

Who may be eligible for Patient Assistance Connection?

In order to be eligible for this portion of the Program, you must meet the following requirements:

- You must be a resident of the US or the US territories and be under the care of a licensed HCP authorized to prescribe, dispense, and administer medicine in the US.
- You must have an annual household income of [≤400%] of the current Federal Poverty Level. If you may be eligible for Medicaid, you will be required to provide documentation of Medicaid denial before being assessed for patient assistance eligibility.
- If you are enrolled in Medicare Part D, you may also be eligible based on the income criteria noted above.
- You must have no insurance coverage or, for commercially insured patients, have no access to the prescribed product or treatment via your insurance.
- For vaccines, you must be 19 years of age or older (except for IMOVAX® Rabies).
- For Thyrogen[®], you must be 18 years of age or older.

How do I apply?

To apply for Patient Assistance Connection, all information must be complete and include the following:

Patient Information:

• Complete all relevant information on page 2, and sign and date the REQUIRED patient authorizations for HIPAA consent and income verification on page 2.

Healthcare Provider:

- Ask your HCP to complete page 3 and sign and date it.
- Ask your HCP to mail or fax your completed application (only pages 2 and 3 are needed).

Missing information may delay processing of your application. **Do not include patient medical records with this application.** Your completed application may be submitted by your HCP as follows:



US Mail

Sanofi Patient Connection PO Box 222138, Charlotte, NC 28222-2138



Fax

1.888.847.1797

What happens next?

When we receive your application, we will review it to see if you qualify for Patient Assistance Connection. If you are eligible:

- 1. You and your HCP will receive a letter notifying you of enrollment. If you are a Medicare Part D patient, your plan sponsor will also receive a letter notifying it of your enrollment.
- 2. You will be enrolled for 12 months. If you are a Medicare Part D patient, you will be enrolled through the end of the calendar year.
- 3. Your medication will be sent directly to your HCP's office in approximately 5-7 business days from when you are approved.

If you do not qualify for Patient Assistance Connection, we will send you and your HCP a letter with the reason for denial.

Note: Sanofi Patient Connection offers patients eligible for patient assistance programs a safe way to dispose of needles through the Sharps program. If you sign up for the Sharps program, you will receive a separate shipment for the Sharps container in order to dispose of your needles.

DO NOT INCLUDE PATIENT MEDICAL RECORDS WITH THIS APPLICATION.





PATIENT TO FILL OUT						
Section 1. Patient Information						
Patient first name MI		Last name				
SSN		DOB				
Address			City			
State Zip		Preferred language (if no	t English)			
Phone number ()						
Email						
Household size 1 2 3 4 5	Other:	Annual household income	e			
I permit Sanofi Patient Connection to speak with the following person and/or organization about the information on this application and the status of my application request.						
Patient representative/organization name	Relationship	to patient	Phone			
Patient Authorizations Sanofi Patient Connection does <u>not</u> charge any fees for this send by a third party completing this application on your behalf are not. I have read and agree to the HIPAA Consent included in Section (REQUIRED) [1 of 3] Patient signature/Legal representative if patient is <18 years I have read and agree to the Income Verification included in Section (REQUIRED) [2 of 3] Patient signature/Legal representative if patient is <18 years	tted to Sanofi. I have read and agree to the Patie	ont Certifications regarding receiving on the connection included in Section 9 on page 5.				
Section 2. Insurance Information Insurance? Yes No If yes, is it Me	edicare Part D?					
Primary insurance name		Secondary insurance na	me			
Insurance phone ()		Insurance phone ()				
Policy ID # Group #		Policy ID #	Group #			
Policyholder name (first/last)		Policyholder name (first/la	ast)			
Relationship to patient DOB		Relationship to patient	DOB			
Section 3. Resource Connection [In order to fill out information below, patient signature required in Section 1.] Do you want to participate in the Sharps needle disposal program? Yes No Please note: You will receive a separate call from a Program associate with contact information for helpful resources checked on your application.						
If yes, please mark which resources you may be interested in, if available:						
Clinical Support Services	Transportation		Health Supplies			
Nutritional Supplements (groceries, food banks, etc)	Home Care Se (shelter, utilities		Other (please elaborate):			

DO NOT INCLUDE PATIENT MEDICAL RECORDS WITH THIS APPLICATION.





PRESCRIBER TO FILL OUT

Please check the appropriate box (prescriber and patient signature required for all applications)

Patient Assistance

No cost medication program. Check this box for no cost medication.

Benefits Verification (BV) and Patient Assistance

Insurance coverage research and no cost medication program. Check this box if the patient has insurance coverage.

BV only

Insurance coverage research program. Check this box if only insurance coverage research is desired.

Section 4.	Treatment	and Pres	cribing	Informatior	ı (See	Section 6	for supporte	ed products)
					i i			

Patient name	DOB		
Product #1	Vials	Product #2	Vials
ICD-10 Code	Pens N/A	ICD-10 Code	Pens N/A
Frequency	Frequency		
Dosage (# of units per day) Qty		Dosage (# of units per day) Qty	

Section 5. Prescriber Information

Prescr	iber name	State where licensed				
Site/facility name			Office contact email			
Туре	Clinic	Physician office	Outpatient hospital	Inpatient hospital	Phone ()	
Facility	y address	*			Fax(
City				State	Zip Code	
Licens	e #	NF	PI #	Tax ID#	DEA#	

^{*}Sanofi product must be shipped to the signing prescriber's office or hospital address authorized by the prescriber and not to a third party.

I certify that the information provided is current, complete, and accurate to the best of my knowledge. I certify that the Sanofi product is medically necessary for this patient and that I am authorized under state law to prescribe and dispense the requested medication. I certify that I have obtained from my patient all required written authorization for the release of my patient's personal identification, medical, and insurance information to Sanofi US and/or Sanofi Cares North America and their agents and representatives. I understand that any information provided is for the sole use of the Program to verify my patient's insurance coverage, to assess, if applicable, patient's eligibility for participation in the Patient Assistance Program and to otherwise administer the Sanofi Patient Connection Program and related services. I understand that I am under no obligation to prescribe any Sanofi product and that I have not received, nor will I receive, any benefit from Sanofi or their agents or representatives for prescribing a Sanofi product. The facility address noted above in Section 5 is my office or hospital address. My signature certifies that any prescription products received from this Program will be used for the above-named patient only and will not be resold nor offered for sale, trade, or barter and will not be returned for credit, nor will payment be sought from any payer, patient, or other source for product received from the Program.

HCP SIGN (REQUIRED)

Prescriber signature (REQUIRED - no stamps)

Printed name

Date

Section 6. Products Available With Sanofi Patient Connection

- Adacel® (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed)
- Admelog® (insulin lispro injection) 100 Units/mL
 Apidra® (insulin glulisine injection) 100 Units/mL
- Imovax® Rabies Vaccine [Human Diploid Cell]
- Lantus® (insulin glargine injection) 100 Units/mL
- Lovenox[®] (enoxaparin sodium injection)*1
- MenQuadfi[®] (Meningococcal [Groups A, C, Y, W] Conjugate Vaccine)
- Mozobil® (plerixafor injection)¹
- Multaq® (dronedarone) Tablets*
- Pentacel[®] Diptheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine
- Priftin® (rifapentine) Tablets
- Soliqua® 100/33 (insulin glargine & lixisenatide) injection 100 Units/mL and 33 mcg/mL
- Tenivac® (tetanus and diphtheria toxoids adsorbed)
- Thymoglobulin® [Anti-Thymocyte Globulin (Rabbit)]*,1
- Thyrogen® (thyrotropin alfa)
- Toujeo® (insulin glargine injection) 300 Units/mL (1.5 mL or 3.0 mL pens)**

*Please see full US prescribing information, including Black Box warning.

*Regular SoloStar® is packaged as 2 pens per pack 900 units/pen; dials up to 160 units per single injection; Max pen dials in 2-unit increments.

"If applying for Drug Replacement (Lovenox*, Mozobil*, and Thymoglobulin*), a copy of the claim, denial, flow sheet(s), and drug dispensing log (with patient name, date of service, product NDCLot #, total dosage) must be submitted.

Full U.S. prescribing information for all Sanofi Patient Connection supported products can be accessed at www.sanofipatientconnection.com/medications-available. Sanofi Patient Connection will provide assistance for any medically appropriate use as described in the prescribing information.

Additional Information

- Sanofi Patient Connection ships most medications in a 90-day supply.
- · A representative from Sanofi may contact you for follow-up on any adverse event you may report regarding a Sanofi product.

DO NOT INCLUDE PATIENT MEDICAL RECORDS WITH THIS APPLICATION.







Section 7. Authorization to Use and Disclose Health Information (REQUIRED)

Patient: Please read the following carefully, then date and sign where indicated in Section 1 on page 2.

HIPAA Consent: I authorize my healthcare providers and staff; my health insurer, health plan, or programs that provide me health benefits (together, "Health Insurers") to disclose to, Sanofi US, its affiliated companies (ie, Sanofi Pasteur U.S. and Genzyme, a Sanofi Company), Sanofi Cares North America, and authorized third party agents involved in administration of this Program, (collectively "Program Sponsor"), health information about me, including information related to my medical condition, treatment, health insurance coverage, claims, prescriptions, and referral to and enrollment in this Program for purposes of determining my participation in, and administering, the Program, which may include contacting me as well as my doctor/healthcare provider, office/hospital staff, insurer (public/private) or others. I understand a representative from Sanofi may contact me for follow-up on any adverse event I may report regarding a Sanofi product. I authorize and consent to release of identifiable information about me including medical, financial and insurance records and information as required for participation in the Program. I understand that identifiable information about me will be kept confidential and will not be further used or disclosed except to administer the Program, or as required by law. I understand that information I authorize to be disclosed may be re-disclosed and is no longer protected by Federal privacy regulations. I agree that this authorization is voluntary and that I may refuse to sign this authorization. Refusal to sign will not affect my ability to obtain treatment but I will not be able to participate in this Program. Unless revoked, this authorization shall remain in effect throughout my participation in the Program, including subsequent reapplication as required. I may withdraw this authorization at any time by written notification to my doctor/healthcare provider; however, withdrawal of authorization will terminate my participation in this Program and will not affect information already disclosed under this Authorization.

I understand that it is my responsibility to follow up with my prescriber or the Program to make sure that my re-orders, as appropriate, are requested in a timely manner by my healthcare provider so I do not run out of medication. I understand that Sanofi US and Sanofi Cares North America reserve the right at any time and without notice to modify or change eligibility criteria or discontinue this Program. I understand that I may withdraw (take back) this Authorization at any time by calling 1.888.847.4877.





Section 8. Income Verification

Patient: Please read the following carefully, then date and sign where indicated in Section 1 on page 2.

Income Verification: I authorize Sanofi Patient Connection (SPC) under the Fair Credit Reporting Act to use my demographic information to access reports on my individual credit history from consumer reporting agencies. I understand that, upon request, SPC will tell me whether an individual consumer report was requested and the name and address of the agency that furnished it. I further understand and authorize SPC to use any consumer reports about me and information collected from me, along with other information they obtain from public and other sources, to estimate my income in conjunction with the Patient Assistance Program eligibility determination process, if applicable. I further understand that no free product may be submitted for reimbursement to any payer, including Medicare and Medicaid; and no free product may be sold, traded, or distributed for sale. If approved for the SPC Patient Assistance Program, I will not seek to have the value of any medication provided to me under this program counted toward my true-out-of-pocket (TrOOP) cost for prescription drugs for my Medicare Part D Plan. Continuation in the SPC Patient Assistance Program is conditioned upon timely verification of income. In addition, I agree to notify SPC if my insurance situation changes.

Section 9. Patient Certifications

Patient: Please read the following carefully, then date and sign where indicated in Section 1 on page 2.

I authorize the Program to contact me by mail, telephone, or email, with information about the Program, disease state, and products, promotions, services, and research studies, and to ask my opinion about such information and topics, including market research and disease-related surveys. I further authorize the Program to de-identify my health information and use it in performing research, including linkage with other de-identified information the Program receives from other sources, education, business analytics, marketing studies, or for other commercial purposes. I understand that entities operating or administering parts of the Program may share identifiable health information with one another in order to de-identify it for these purposes and as needed to perform the Services or to send the communications listed above (the "Communications"). I understand and agree that the Program may use my health information for these purposes and may share my health information with my doctors, specialty pharmacies, and insurers. I understand that I may be contacted by the Program in the event that I report an adverse event associated with a Sanofi product.

I understand that I do not have to opt in to receive the Communications, and that I can still receive patient assistance through the Program, as prescribed by my physician. I may opt out of receiving the Communications offered by the Program, at any time by notifying a Program representative by telephone at 1-800-633-1610 or by mailing a letter to Sanofi US Customer Services, P.O. Box 5925 Mailstop 55A-220A5, Bridgewater, NJ 08807-5925. I also understand that the Services may be revised, changed, or terminated at any time.